- Home
- AKBA vs VINP Comparison
AKBA vs VINP Comparison
Compare AKBA & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- VINP
- Stock Information
- Founded
- AKBA 2007
- VINP 2009
- Country
- AKBA United States
- VINP Brazil
- Employees
- AKBA N/A
- VINP N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- VINP Investment Managers
- Sector
- AKBA Health Care
- VINP Finance
- Exchange
- AKBA Nasdaq
- VINP Nasdaq
- Market Cap
- AKBA 669.7M
- VINP 634.1M
- IPO Year
- AKBA 2014
- VINP 2021
- Fundamental
- Price
- AKBA $3.69
- VINP $9.41
- Analyst Decision
- AKBA Strong Buy
- VINP Strong Buy
- Analyst Count
- AKBA 5
- VINP 2
- Target Price
- AKBA $6.90
- VINP $13.25
- AVG Volume (30 Days)
- AKBA 6.0M
- VINP 52.2K
- Earning Date
- AKBA 05-08-2025
- VINP 05-12-2025
- Dividend Yield
- AKBA N/A
- VINP 6.54%
- EPS Growth
- AKBA N/A
- VINP N/A
- EPS
- AKBA N/A
- VINP 0.38
- Revenue
- AKBA $184,909,000.00
- VINP $126,696,258.00
- Revenue This Year
- AKBA $23.32
- VINP $70.28
- Revenue Next Year
- AKBA $49.90
- VINP $14.37
- P/E Ratio
- AKBA N/A
- VINP $25.30
- Revenue Growth
- AKBA N/A
- VINP 57.51
- 52 Week Low
- AKBA $0.80
- VINP $8.66
- 52 Week High
- AKBA $3.73
- VINP $11.62
- Technical
- Relative Strength Index (RSI)
- AKBA 83.69
- VINP 35.82
- Support Level
- AKBA $2.76
- VINP $9.43
- Resistance Level
- AKBA $3.73
- VINP $9.95
- Average True Range (ATR)
- AKBA 0.18
- VINP 0.24
- MACD
- AKBA 0.07
- VINP -0.05
- Stochastic Oscillator
- AKBA 96.67
- VINP 0.00
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.